Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

被引：24
|
作者：
Faivre-Finn, C. [1 ,2 ]
Vicente, D. [3 ]
Kurata, T. [4 ]
Planchard, D. [5 ]
Paz-Ares, L. [6 ,7 ]
Vansteenkiste, J. F. [8 ]
Spigel, D. R. [9 ,10 ]
Garassino, M. C. [11 ]
Reck, M. [12 ]
Senan, S. [13 ]
Naidoo, J. [14 ,15 ,16 ]
Rimner, A. [16 ]
Wu, Y-L. [17 ,18 ]
Gray, J. E. [19 ]
Ozguroglu, M. [20 ]
Lee, K. H. [21 ]
Newton, M. [22 ]
Wang, L. [22 ]
Thiyagarajah, P. [23 ]
Antonia, S. J. [19 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Hosp Univ Virgen Macarena, Seville, Spain
[4] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[5] Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France
[6] Univ Complutense, Hosp Univ 12 Octubre, CiberOnc, Madrid, Spain
[7] CNIO, Madrid, Spain
[8] Univ Hosp KU Leuven, Dept Resp Oncol, Leuven, Belgium
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Tennessee Oncol, Nashville, TN USA
[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[12] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany
[13] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands
[14] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[15] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[16] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
[17] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Dept Pulm Oncol, Guangzhou, Peoples R China
[18] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[19] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[20] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey
[21] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[22] AstraZeneca, Gaithersburg, MD USA
[23] AstraZeneca, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA49
引用
收藏
页码：S1178 / S1179
页数：2
相关论文
共 50 条
  • [1] Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
    Faivre-Finn, Corinne
    Vicente, David
    Kurata, Takayasu
    Planchard, David
    Paz-Ares, Luis
    Vansteenkiste, Johan F.
    Spigel, David R.
    Garassino, Marina C.
    Reck, Martin
    Senan, Suresh
    Naidoo, Jarushka
    Rimner, Andreas
    Wu, Yi-Long
    Gray, Jhanelle E.
    Ozguroglu, Mustafa
    Lee, Ki H.
    Cho, Byoung C.
    Kato, Terufumi
    de Wit, Maike
    Newton, Michael
    Wang, Lu
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 860 - 867
  • [2] 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial
    de Wit, M.
    Spigel, D. R.
    Faivre-Finn, C.
    Gray, J. E.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Garassino, M. C.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L
    Oezgueroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S. J.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 109 - 110
  • [3] Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
    Spigel, David R.
    Faivre-Finn, Corinne
    Gray, Jhanelle Elaine
    Vicente, David
    Planchard, David
    Paz-Ares, Luis G.
    Vansteenkiste, Johan F.
    Garassino, Marina Chiara
    Hui, Rina
    Quantin, Xavier
    Rimner, Andreas
    Wu, Yi-Long
    Ozguroglu, Mustafa
    Lee, Ki Hyeong
    Kato, Terufumi
    de Wit, Maike
    Macpherson, Euan
    Newton, Michael
    Thiyagarajah, Piruntha
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
    Gray, Jhanelle E.
    Villegas, Augusto
    Daniel, Davey
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Planchard, David
    Paz-Ares, Luis
    Faivre-Finn, Corinne
    Vansteenkiste, Johan F.
    Spigel, David R.
    Wadsworth, Catherine
    Taboada, Maria
    Dennis, Phillip A.
    Ozguroglu, Mustafa
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : 288 - 293
  • [5] 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study
    de Wit, M.
    Spigel, D.
    Faivre-Finn, C.
    Gray, J.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J.
    Garassino, M.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L.
    Ozguroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S8 - S9
  • [6] PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
    Raben, D.
    Faivre-Finn, C.
    Spigel, D.
    Daniel, D.
    Villegas, A.
    Vincente, D.
    Hui, R.
    Carpeno, J. de Castro
    Murakami, S.
    Paz-Ares, L.
    Ozguroglu, M.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Poole, L.
    Wadsworth, C.
    Dennis, P. A.
    Antonia, S. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (05): : 1607 - 1608
  • [7] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24): : 2342 - 2350
  • [8] Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
    Garassino, Marina C.
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Bischoff, Helge
    Reinmuth, Niels
    Cove-Smith, Laura
    Mansy, Talal
    Cortinovis, Diego
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1415 - 1427
  • [9] COST-EFFECTIVENESS OF DURVALUMAB FOLLOWING CHEMORADIOTHERAPY IN UNRESECTABLE STAGE III NSCLC PATIENTS IN THE US: AN UPDATE BASED ON 4-YEAR SURVIVAL DATA
    Seal, B.
    Mooradian, M. J.
    Van Keep, M.
    Dunlop, W.
    Brannman, L.
    Yong, C.
    VALUE IN HEALTH, 2021, 24 : S26 - S27
  • [10] Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
    Antonia, S.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    De Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y.
    Karapetis, C.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J.
    Paz-Ares, L.
    Carpeno, J. De Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D.
    Wadsworth, C.
    Taboada, M.
    Dennis, P.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S184
12345